Literature DB >> 18642667

[Following-up of nosocomial lower respiratory infection in patients with hematological malignancy after chemotherapy].

Qun Lu1, Lian-sheng Huang, Rong Zhang, Gen-bo Xu, Xiao-ying Zhao.   

Abstract

OBJECTIVE: To observe and investigate the risk factors and pathogen diversification of nosocomial lower respiratory infections in patients with hematological malignancy after chemotherapy.
METHODS: Respiratory tract microbial population of fifty patients with different kinds of hematological malignancy and para-prepared to chemotherapy was quantitatively analyzed before and after chemotherapy at an arranged time from April, 2004 to December, 2005. Susceptibility test was determined for bacterium of nosocomial infection, and the homology of the same species of the bacteria was analyzed by a pulsed field gel electrophoresis (PFGE).
RESULTS: Incidence rate of lower respiratory infections in patients with the hematological malignant after chemotherapy was 16%. The major nosocomial infectious pathogens were Acinetobacter spp; Escherichia coil and Fungus. Among them, Acinetobacter spp, were highly resistant to cephalosporins, quinolones, aminoglycosides, carbapenems and antibiotic with enzyme inhibitor, respectively but susceptible to Cefoperazone/Sulbactam belonging to antibiotic with enzyme inhibitor. And it was shown that there were two clones by the pulsed field gel electrophoresis (PFGE).
CONCLUSION: Following-up of nosocomial lower respiratory infection in patients with hematological malignancy after chemotherapy might offer theoretical evidence for the rational use of antibiotics and the control of nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18642667

Source DB:  PubMed          Journal:  Zhonghua Yu Fang Yi Xue Za Zhi        ISSN: 0253-9624


  1 in total

1.  Molecular epidemiology of aminoglycosides resistance in acinetobacter spp. With emergence of multidrug-resistant strains.

Authors:  R Moniri; R Kheltabadi Farahani; Gh Shajari; Mh Nazem Shirazi; A Ghasemi
Journal:  Iran J Public Health       Date:  2010-06-30       Impact factor: 1.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.